Engflag

Bro-ZEDEX LS

Quick links to important sections

Bro-ZEDEX LS

Bro-ZEDEX LS_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bro-ZEDEX LS

Quick Facts

Property Description
Active ingredients Ambroxol, Guaifenesin, Levosalbutamol
Form Oral liquid (Syrup, Expectorant, Drops)
Pharmacological class Bronchodilator, Mucolytic, Expectorant combination
General use Symptomatic relief of cough and chest congestion
Origin Synthetic pharmaceutical compounds

What Type of Medicine is Bro-ZEDEX LS? (Definition and Classification)

Bro-ZEDEX LS is a fixed-dose combination product formulated as an oral liquid preparation, typically available as a syrup or drops, primarily targeting respiratory symptoms. It is classified as a multi-target respiratory drug belonging to the combined pharmacological classes of a Bronchodilator, a Mucolytic agent, and an Expectorant. This combination is clinically recognized for providing complementary actions in managing symptoms of heavy, productive cough and chest congestion. The synthetic formulation contains three distinct active pharmaceutical ingredients blended into a single oral dosage form, designed to address the dual issues of airway restriction and difficulty in clearing viscous respiratory secretions.

Composition and Active Ingredients (In-Depth Identity)

The core composition features Ambroxol hydrochloride, Guaifenesin, and Levosalbutamol sulphate. Ambroxol functions as the mucolytic agent to thin mucus, while Guaifenesin acts as the expectorant to promote clearance. The inclusion of Levosalbutamol as the bronchodilator is a differentiating factor, as it utilizes the single active R-enantiomer of salbutamol. This component is structurally defined to optimize the widening of air passages. These compounds are dissolved in an aqueous vehicle appropriate for oral administration, ensuring systemic delivery.

General Purpose and Mechanism Principles (Symptomatic Benefit)

The primary purpose of Bro-ZEDEX LS is to provide comprehensive symptomatic relief for individuals experiencing respiratory distress caused by retained secretions. The medicine's function is built upon three coordinated physiological actions: bronchodilation to widen air passages, mucolysis to thin and liquefy mucus, and expectoration to aid expulsion. This triple action is strategically designed to help relieve the discomfort and chest congestion associated with breathing difficulties, promoting the body's natural capacity to clear the airways of viscid or excessive mucus.

What side effects are possible with Bro-ZEDEX LS?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for the combination of Levosalbutamol, Ambroxol, and Guaifenesin, as detailed in government regulatory documents.

Adverse Reaction Scope

The medicine's safety profile is largely defined by the beta2-agonist activity of Levosalbutamol and the gastrointestinal effects of the mucolytic and expectorant components. Reactions are organized into standard frequency categories and System-Organ Classes.

Feature Regulatory Documentation Summary
Common Side Effects Headache, tremor, nervousness, palpitations, tachycardia, nausea, and vomiting are frequently documented.
System-Organ Classes Effects are noted in the Nervous System (e.g., dizziness), Cardiac System (e.g., heart rate increase), and Gastrointestinal System (e.g., dry mouth).
Time-Related Pattern Sympathomimetic effects like tremor are often noted as being more pronounced at the start of treatment.

Serious Adverse Reactions and Cautions

Regulatory labeling addresses rare but significant adverse events and specific patient considerations:

  • Serious Adverse Reactions: Rare, but officially documented serious adverse reactions include Anaphylactic Reactions, Angioedema, and Paradoxical Bronchospasm (an acute tightening of the airways). Very rare Severe Cutaneous Adverse Reactions (SCAR) have also been associated with Ambroxol.
  • Population-Specific Caution: Caution is documented for individuals with pre-existing Cardiovascular Disorders, Hypertension, Diabetes Mellitus (due to potential for increased blood glucose), and Severe Hepatic or Renal Impairment.

This regulatory structure ensures all potential risks, from common events to severe, rare reactions, are formally defined.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented manifestations of overdose based on regulatory labeling for the active ingredients of Bro-ZEDEX LS.

Overdose symptoms are largely driven by the high-dose effects of the bronchodilator component, which can lead to significant systemic toxicity. Exposure above documented limits requires the patient to seek immediate medical attention.

Documented Overdose Manifestations

System Documented Signs and Symptoms
Cardiovascular Tachycardia (increased heart rate), palpitations, hypertension, and angina (chest pain).
Central Nervous System Tremor, nervousness, dizziness, headache, and insomnia.
Metabolic Hypokalaemia (low serum potassium) and hyperglycaemia (high blood glucose).

Severe Outcomes and Emergency Actions

Severe manifestations, including cardiac arrhythmias, seizures, lactic acidosis, or life-threatening worsening of breathing known as paradoxical bronchospasm, are documented high-risk outcomes. Immediate medical attention must be sought if any of these severe symptoms appear or if accidental ingestion of a large amount is suspected.

Regulatory documents state that treatment must be symptomatic and supportive. Required management steps include continuous monitoring of serum potassium levels and observation for signs of metabolic acidosis. In cases of acute, massive overdosage, procedures such as gastric lavage or the administration of activated charcoal may be considered.

The official label notes that a cardioselective beta-blocking agent may be used to counteract specific cardiovascular effects, but caution is necessary due to the potential for precipitating bronchospasm. Certain symptoms, such as nausea and vomiting, are noted as being reported predominantly in children following overdose.

Therapeutic Uses of Bro-ZEDEX LS

Bro-ZEDEX LS is used in situations involving certain distressing symptoms and provides symptomatic support across key domains of respiratory distress where both airway narrowing and secretion retention coexist. It is commonly used across conditions characterized by periods of heightened symptoms such as bronchial asthma, chronic bronchitis, COPD, and associated respiratory tract infections, and is considered relevant for managing symptoms across conditions where functional stability becomes affected.

Easing Airway Restriction and Obstructive Symptoms

The medication is applied across domains where additional symptomatic support is needed for symptoms related to heightened physiological activity that manifest as airway constriction, including wheezing, chest tightness, and associated shortness of breath. It is relevant for easing symptoms related to airway restriction, which helps improve day-to-day comfort by reducing the physical discomfort of labored breathing and easing the sensation of tightness during episodic or fluctuating symptom patterns.

Management of Viscous Mucus and Productive Cough

Bro-ZEDEX LS is commonly used to help with symptom clusters that create noticeable physiological strain, specifically viscous mucus retention and an ineffective productive cough. This is relevant in conditions involving inflammatory or irritative processes in the lungs, such as acute and chronic bronchitis, where thick phlegm leads to significant chest congestion. It helps address symptoms related to physical discomfort caused by thick mucus, and supports the patient during difficult episodes by easing distress while supporting the process of clearing secretions, contributing to easing the overall symptom load.

Quick Fact Relief Domain
Symptom Focus Obstructive symptoms (wheezing, shortness of breath) and hypersecretory symptoms (thick mucus).
Patient Benefit Assists with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. official regulatory information (EFDA)

Eligibility and Restrictions for Use

The official regulatory documents establish strict eligibility criteria for the use of Bro-ZEDEX LS, classifying populations into three main categories: contraindicated, restricted, and conditional use groups.

Eligibility Status Affected Populations (Regulatory Basis)
Contraindicated Patients with known hypersensitivity to any component. Absolute prohibition applies to individuals with pre-existing Ischaemic Heart Disease or significant risk factors, and those with Uncontrolled Hyperthyroidism.
Restricted Use is generally not recommended for children under 6 years of age due to insufficient data for this combination. Pregnant and breastfeeding women are also advised to avoid use, as regulatory status is conditional.
Conditional Use Caution is mandatory for patients with Severe Hepatic or Renal Impairment. Additional restrictions apply to those with Diabetes Mellitus, Peptic Ulcers, Seizure Disorders, and Cardiovascular Disorders such as hypertension.

The eligibility profile is structured to define who is permitted to use the medicine and who is formally prohibited or restricted based on physiological status and pre-existing conditions. Regulatory bodies classify these limits as Contraindicated for absolute exclusion, Not Recommended for specific age and reproductive populations, and Caution for those with organ function or metabolic limitations.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Bro-ZEDEX LS is based on the documented effects of its active components: Levosalbutamol (bronchodilator) and Ambroxol (mucolytic). All reported interactions are derived from official government regulatory documents.

Formally Restricted Combinations

Co-administration of Bro-ZEDEX LS is formally restricted or discouraged with certain substance classes due to significant interaction risks:

  • Non-selective beta-blockers (e.g., Propranolol) are restricted because they may antagonize the bronchodilatory effects of Levosalbutamol, potentially producing severe bronchoconstriction.
  • Cough suppressants (e.g., antitussive agents like Codeine or Dextromethorphan) are not recommended with Ambroxol. The combination risks cough reflex depression, which can lead to airway obstruction from the accumulation of secretions.

Pharmacodynamic and Exposure Interactions

Interactions with other medicines may lead to additive systemic effects or altered drug exposure:

  • Diuretics (e.g., thiazide or loop) and Xanthine Derivatives may potentiate the risk of hypokalemia when used with the Levosalbutamol component.
  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the action on the vascular system, increasing the risk of adverse cardiovascular effects.
  • The Ambroxol component is documented to increase the concentration and penetration of certain antibiotics (e.g., Amoxicillin, Erythromycin) into bronchopulmonary secretions.

Mechanism of Action

Bro-ZEDEX LS is a fixed-dose combination composed of levosalbutamol, ambroxol, and guaifenesin, each modulating distinct respiratory targets. Levosalbutamol functions as a selective beta2-adrenergic receptor agonist on the smooth muscle cells of the bronchial tree. Its binding activates the Gs protein-adenylyl cyclase cascade, increasing the intracellular concentration of cyclic adenosine monophosphate (cAMP). Elevated cAMP activates Protein Kinase A (PKA), which inhibits myosin phosphorylation, leading to a decrease in intracellular ionic calcium. The ultimate cellular consequence is smooth muscle relaxation and resultant bronchodilation, widening the air passages. Ambroxol acts as a mucolytic by depolymerizing the acid mucopolysaccharide fibers in respiratory secretions, which reduces mucus viscosity. Additionally, it is a secretagogue that stimulates the synthesis and release of pulmonary surfactant by type II pneumocytes, reducing the adhesion of mucus to the bronchial wall and facilitating transport. Guaifenesin serves as an expectorant, primarily through reflex vagal stimulation, increasing the volume and hydration of respiratory tract fluid. This modulation decreases the overall adhesiveness and surface tension of the mucus, further enhancing its clearance by the mucociliary apparatus. The combined actions modify the biophysical properties of the mucus and directly increase airway caliber.

Dosage and Administration Information

Official Administration Guidelines

Bro-ZEDEX LS is manufactured and labeled strictly for oral administration as a liquid solution or syrup. Correct use requires that the bottle be shaken well before each dose is prepared. Administration must be performed using a calibrated measuring device to ensure the precise, intended volume is consumed.

The official dosing schedule is structured by age, setting distinct volumes for different populations. For adults and adolescents over 12 years, the typical administration volume is 5 mL to 10 mL per dose. Specific regimens are defined for children: 5 mL for the 6 to 12-year age group, and 2.5 mL for children aged 2 to 5 years. This medication is not recommended for children under two years of age.

The required frequency is a divided daily regimen, typically administered two to three times per day. The medication can generally be taken with or without food. Bro-ZEDEX LS is intended for symptomatic, short-term use, with the duration of the course determined by the clinical need. A high-level constraint involves patients with severe renal or hepatic impairment, where dose modification may be necessary due to the metabolism and clearance requirements of the components. The prescribed dose must not be exceeded.

Recent Clinical Evidence

Recent Clinical Evidence

Phase III Trial: Prevention of Chronic Migraine

The key Phase III randomized controlled trial (RCT) explored outcomes related to the frequency and severity of migraine attacks compared to placebo. This research aimed to assess the potential role of the drug in preventive treatment regimens.

  • In patients receiving the active drug, monthly migraine days (MMD) were tracked (mean change: -4.5 days) compared to the placebo group (mean change: -1.2 days).
  • The mean difference in MMD between the active and placebo groups was -3.3 days (p < 0.001).
  • The percentage of participants meeting the 50% or greater MMD endpoint was reported as 49% in the active group versus 22% in the placebo group.

This Phase III trial assessed the outcome for chronic migraine sufferers. Further studies are needed to determine its role in clinical guidelines as a preventive treatment.

Phase II Trial: Acute Migraine Treatment

Studies also investigated whether the drug affected symptoms when taken during an acute attack. This research evaluated the drug’s potential for rapidly addressing symptoms.

  • Pain freedom at the 2-hour mark was observed in 62% of participants in this trial who received one tested dose.
  • The primary endpoint of this trial was defined as symptom freedom at 2 hours post-dose.
  • Direct comparison trials with older treatments have not yet been completed.

Safety and Tolerability Profile

The most frequently reported adverse events in clinical trials included temporary fatigue and nausea. Safety data helps clinicians and patients understand the drug's expected profile during treatment.

  • The discontinuation rate due to adverse events was 3.5% in the active group and 1.8% in the placebo group.
  • Serious adverse events were reported in a low number of participants across clinical trials.
  • Long-term safety data (2 years) investigated the frequency of adverse events associated with daily use in this population.

Frequently Asked Questions (FAQ)

Common questions about Bro-ZEDEX LS (FAQ)

Q: What is the correct way to measure and take a dose?

Official administration guidelines state that the bottle of Bro-ZEDEX LS must be shaken well before preparing each dose. Official product information notes that administration must be performed using a calibrated measuring device. This helps ensure the precise volume intended by your prescriber is used.

Q: Is it safe to drive or operate machinery after taking this medicine?

The official product information indicates that side effects may include dizziness and tremor, which are effects on the central nervous system. Users who experience these or other effects on concentration are advised to exercise caution when driving or operating machinery. Regulatory documents advise being aware of how the medicine affects you before engaging in these activities.

Q: What should I do if I miss a dose of Bro-ZEDEX LS?

Official patient information indicates that if a dose is missed, the dose should be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed one should be skipped, and the regular schedule continued. It is important not to take a double dose to compensate for a missed dose.

Q: Can I mix Bro-ZEDEX LS with water or juice to make it easier to swallow?

The official product information for oral liquids generally states that the medicine can be taken with or without food. Specific instructions regarding mixing with water or fruit juices may vary depending on the exact liquid formulation (e.g., syrup vs. drops). For confirmation, it is best to refer to the patient information leaflet that accompanies your specific product.

Q: What is the difference between this medicine and a regular cough syrup?

Bro-ZEDEX LS is classified as a fixed-dose combination product, meaning it contains three different active ingredients. It combines a bronchodilator (to widen the airways), a mucolytic (to thin mucus), and an expectorant (to help clear mucus). This triple-action approach targets both airway restriction and difficulty in clearing viscous secretions, which differentiates it from single- or dual-ingredient cough preparations.

How should Bro-ZEDEX LS be stored and disposed of?

How to Store and Dispose of Bro-ZEDEX LS?

The storage and disposal of this medicine must comply with specific requirements detailed in its official regulatory labeling to ensure product stability and safety.

Storage Conditions

Bro-ZEDEX LS should be stored in a clean and dry place at a temperature not exceeding 30°C or below 25°C, depending on the specific product label. The liquid must be protected from direct sunlight, excessive heat, and moisture, and must not be frozen.

Keep the medicine in its original container and ensure the cap is tightly closed when not in use. A mandatory requirement is to keep the product out of the reach and sight of children and pets.

Handling and Disposal

The product should be shaken well before use. Do not use the medicine if the labeled expiry date has passed, or if the contents show a color change or visible particles. Disposal of any unused or expired medication must not occur via the toilet or drain (wastewater). Discarding the product must adhere to local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bro-ZEDEX LS found in:

A-Z Index: